|
RBM25 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.00739425082475E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.76520037370653E-10 |
| Normal-vs-Stage2 |
3.55549999997429E-07 |
| Normal-vs-Stage3 |
1.5736301151037E-12 |
| Normal-vs-Stage4 |
6.42509999648766E-08 |
| Stage1-vs-Stage2 |
5.725600E-01 |
| Stage1-vs-Stage3 |
1.607660E-02 |
| Stage1-vs-Stage4 |
2.115000E-01 |
| Stage2-vs-Stage3 |
2.479000E-01 |
| Stage2-vs-Stage4 |
5.936600E-01 |
| Stage3-vs-Stage4 |
6.152200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.96331881044898E-12 |
| Normal-vs-AfricanAmerican |
5.54400000000177E-05 |
| Normal-vs-Asian |
3.59749999999659E-05 |
| Caucasian-vs-AfricanAmerican |
9.878400E-01 |
| Caucasian-vs-Asian |
2.766200E-01 |
| AfricanAmerican-vs-Asian |
4.477200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.39130004686672E-09 |
| Normal-vs-Female |
2.39341879648691E-12 |
| Male-vs-Female |
7.491000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.06580000380774E-09 |
| Normal-vs-Age(41-60Yrs) |
3.48440054587229E-10 |
| Normal-vs-Age(61-80Yrs) |
5.64539526237695E-11 |
| Normal-vs-Age(81-100Yrs) |
3.68839999653758E-08 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.252000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.755900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.782250E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.774600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.403500E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.793600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.78240000000751E-05 |
| Classical-VS-Follicular |
4.060200E-01 |
| Classical-VS-Other |
8.296800E-01 |
| Classical-VS-Normal |
1.08480002758427E-10 |
| Tall-VS-Follicular |
6.917600E-03 |
| Tall-VS-Other |
8.948000E-02 |
| Tall-VS-Normal |
3.45534711954087E-12 |
| Follicular-VS-Other |
9.315800E-01 |
| Follicular-VS-Normal |
1.3557000000386E-07 |
| Other-VS-Normal |
1.818480E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.20097331658098E-12 |
| Normal-vs-N1 |
1.350980E-04 |
| N0-vs-N1 |
1.601970E-01 |
|
|
